J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
L o r v o t u z u m a b m e r t a n s i n e
2 l a n g u a g e s
● ا ل ع ر ب ي ة ● I t a l i a n o
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate . It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine ; when it is attached with the thioether linker, SMCC, it is emtansine.)[citation needed
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer ).[1] [2]
It has been granted Orphan drug status for Merkel cell carcinoma .[3]
It has reported encouraging Phase II results for small-cell lung cancer .[4]
References
[ edit ]
^ "ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC" . News-Medical.net . 8 March 2010.
^ "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer" . 2009.[permanent dead link
t
e
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Lorvotuzumab_mertansine&oldid=1157645318 " C a t e g o r i e s : ● D r u g s n o t a s s i g n e d a n A T C c o d e ● A n t i b o d y - d r u g c o n j u g a t e s ● E x p e r i m e n t a l c a n c e r d r u g s ● M o n o c l o n a l a n t i b o d i e s f o r t u m o r s ● M o n o c l o n a l a n t i b o d y s t u b s ● A n t i n e o p l a s t i c a n d i m m u n o m o d u l a t i n g d r u g s t u b s H i d d e n c a t e g o r i e s : ● A l l a r t i c l e s w i t h d e a d e x t e r n a l l i n k s ● A r t i c l e s w i t h d e a d e x t e r n a l l i n k s f r o m J a n u a r y 2 0 1 8 ● A r t i c l e s w i t h p e r m a n e n t l y d e a d e x t e r n a l l i n k s ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● A r t i c l e s w i t h c h a n g e d C A S N o i d e n t i f i e r ● C h e m i c a l s t h a t d o n o t h a v e a C h e m S p i d e r I D a s s i g n e d ● A r t i c l e s w i t h c h a n g e d K E G G i d e n t i f i e r ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● D r u g s w i t h n o l e g a l s t a t u s ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o v e r i f i e d f i e l d s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y ● A l l a r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s ● A r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s f r o m F e b r u a r y 2 0 2 3 ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 3 0 M a y 2 0 2 3 , a t 0 1 : 3 1 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
N
Y (what is this?) (verify)
